Top Canadian Cannabis Stocks to Watch This Week
Canadian cannabis stocks remain in focus this week as sector sentiment continues improving. Several Canadian operators maintain meaningful exposure to the U.S. market through brands and partnerships. Meanwhile, the U.S. cannabis industry continues expanding despite regulatory delays. Total U.S. cannabis sales now exceed $32 billion annually. Importantly, analysts project the market could surpass $50 billion by 2030. That growth outlook keeps Canadian operators relevant for global investors. Recently, renewed federal reform discussions returned to headlines. Cannabis rescheduling remains under active government review. Additionally, lawmakers continue debating banking access and tax reform measures. While timing remains uncertain, momentum has improved compared to prior years. As a result, Canadian cannabis stocks often react sharply to U.S. policy developments. Therefore, investors are watching these names closely for near-term momentum and long-term positioning.
However, cannabis stocks remain volatile and require discipline. Price swings often follow earnings releases, policy headlines, or technical breaks. Therefore, traders should rely on technical analysis to identify higher-probability entries. Key tools include moving averages, volume trends, and support levels. For example, reclaiming the 50-day average can signal improving momentum. Meanwhile, repeated failures at resistance may indicate exhaustion. Just as important, proper risk management remains essential. Traders should define stops before entering positions. Position sizing should reflect volatility and account size. By combining technical signals with risk controls, investors can navigate this sector more effectively. Against this backdrop, three Canadian cannabis stocks stand out this week.
[Read More] Marijuana Stocks For Your 2026 Watchlist
Canadian Cannabis Stocks in Focus: Top Picks to Watch This Week
- Tilray Brands (NASDAQ: TLRY)
- Canopy Growth (NASDAQ: CGC)
- Aurora Cannabis (NASDAQ: ACB)
Tilray Brands (TLRY)
Tilray Brands is a diversified cannabis and consumer products company with a global footprint. The company operates across cultivation, processing, and branded product distribution. Importantly, Tilray has expanded beyond cannabis into beverages and wellness products. This diversification provides additional revenue stability during sector downturns.
In the United States, Tilray maintains exposure through hemp-derived products and select THC offerings. These products are sold through licensed dispensaries in multiple states. Additionally, Tilray’s beverage brands are distributed through mainstream retail channels. As a result, the company’s U.S. presence extends beyond dispensaries alone. Tilray continues forming strategic partnerships to expand national distribution. Therefore, U.S. market access remains central to its long-term strategy. The company trades on the NASDAQ, providing liquidity for U.S. investors. Overall, Tilray blends cannabis, lifestyle, and consumer brands under one platform.
From a financial perspective, Tilray continues navigating a challenging operating environment. Recent revenue results showed modest year-over-year growth. However, the company remains unprofitable as restructuring efforts continue. Encouragingly, adjusted margins improved across several operating segments. Certain business lines moved closer to break-even levels. Meanwhile, Tilray completed a reverse stock split to maintain exchange compliance. Cash flow remains pressured, but cost controls have improved. Beverage and wellness revenue helped offset cannabis pricing pressure. As a result, Tilray’s financials show gradual stabilization. Traders should watch volume and moving averages to confirm momentum shifts.
[Read More] U.S. Cannabis Reform Update: Federal Policy Shifts and What They Mean for Stocks
Canopy Growth (CGC)
Canopy Growth remains one of Canada’s most recognizable cannabis producers. Founded in 2013, the company built a broad portfolio of adult-use and medical brands. Its offerings include flower, vapes, edibles, and infused beverages. These brands serve both recreational and medical consumers globally.
In the United States, Canopy maintains indirect exposure through affiliated entities. These relationships provide access to multiple U.S. dispensaries and branded products. This structure allows participation in the U.S. THC market without direct federal conflict. Additionally, Canopy operates international medical cannabis businesses in Europe and Australia. Therefore, geographic diversification remains a strategic advantage. While U.S. legalization uncertainty persists, Canopy is positioned for upside if reform accelerates.
Financially, Canopy has shown signs of operational improvement. Recent quarterly revenue increased compared to the prior year. Canadian adult-use and medical sales supported growth. Importantly, the company reduced operating expenses meaningfully. This helped narrow operating losses and improve cash flow trends. Although gross margins fluctuated due to sales mix, efficiency improved sequentially. Cash reserves remain healthy relative to debt. However, profitability has not yet been achieved. The stock experienced volatility during 2025, reflecting sector sentiment shifts. Still, improving fundamentals may attract technical traders watching for trend reversals.
[Read More] U.S. Marijuana Stocks Positioned for Growth as Reform Discussions Continue
Aurora Cannabis (ACB)
Aurora Cannabis is a leading Canadian producer focused primarily on medical cannabis. The company operates cultivation and distribution facilities across multiple countries. Its international footprint includes Europe and Australia. This focus provides exposure to regulated medical markets with consistent demand.
Aurora’s direct U.S. cannabis exposure remains limited. However, the company trades on the NASDAQ, giving U.S. investors access. Aurora continues prioritizing regulatory compliance and cultivation efficiency. It also develops medical products targeting specific patient needs. As legalization expands globally, Aurora remains positioned to capture incremental demand.
Recent financial results showed progress toward stabilization. Medical cannabis revenue increased year-over-year. Gross margins improved as higher-margin products gained share. Additionally, Aurora maintained solid cash reserves. This reduced reliance on new financing. Although some international sales faced pressure, domestic medical demand helped offset declines. Net losses narrowed compared to prior periods. Cost discipline remains a core focus. While the stock remained volatile, technical momentum improved at times. Investors should monitor support levels and volume trends closely.
[Read More] Best U.S. Cannabis Stocks to Watch This Week as Legalization Momentum Builds
Final Thoughts
Tilray, Canopy Growth, and Aurora Cannabis each offer unique exposure to evolving cannabis markets. With U.S. legalization headlines returning and technical setups forming, Canadian cannabis stocks remain active trading candidates this week.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
